Aytu BioPharma Q3 2025 Earnings Call Transcript

Quartr
Provided by Quartr
May 14, 2025

Key Takeaways

  • Aytu delivered 32% year-over-year revenue growth to $18.5 million in Q3 FY25, driven by 25% growth in its ADHD portfolio and 77% increase in its pediatric portfolio.
  • The company achieved its second consecutive quarter of positive income from operations ($2.4 million) and third quarter of positive net income ($4 million, $0.65 EPS), reflecting cost reduction initiatives that cut operating expenses by $1.6 million.
  • A2 RxConnect, the in-house patient access platform, drove improvements in gross-to-net economics and prescription fulfillment through a network of ~1,000 independent and regional pharmacies.
  • Strategic moves—halting clinical development, divesting consumer health, outsourcing manufacturing, and refinancing debt—have optimized infrastructure and enabled continued margin expansion.
  • Aytu is actively evaluating complementary CNS-focused assets for in-licensing or acquisition to leverage its specialized salesforce and RxConnect capabilities for future growth.
AI Generated. May Contain Errors.
Earnings Conference Call
Aytu BioPharma Q3 2025
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

Please note this conference is being recorded. I will now turn the conference over to your host, Robert Blum, Investor Relations at Robert, your line, you may begin.

Robert Blum
Managing Partner at Lytham Partners

Thank you very much, and good afternoon, everyone. As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal twenty twenty five third quarter operational and financial results for the period ended 03/31/2025. With us on today's call is Aytu's Chief Executive Officer, Josh Disbrow and Ryan Selhorn, the company's Chief Financial Officer. At the conclusion of today's prepared remarks, we'll open the call for a question and answer session. I'd like to remind everyone that today's call is being recorded.

Robert Blum
Managing Partner at Lytham Partners

A replay of today's call will be available by using the teleconference numbers and conference ID provided in the press release issued earlier today or by utilizing the link on the company's website under Events and Presentations. Finally, I'd also like to call to your attention the customary Safe Harbor disclosure regarding forward looking information. The conference call today will contain certain forward looking statements, including statements regarding the goals, strategies, beliefs, expectations and future potential operating results of Aytu BioPharma. Although the management believes these statements are reasonable based on estimates, assumptions and projections as of today, these statements are not guarantees of future performance. Time sensitive information may no longer be accurate at the time of any telephonic or webcast replay.

Robert Blum
Managing Partner at Lytham Partners

Actual results may differ materially as a result of risks, uncertainties and other factors, including but not limited to the factors set forth in the company's filings with the SEC. Aytu undertakes no obligation to update or revise any of these forward looking statements. With that said, let me turn the call over to Josh Disbrow, Chief Executive Officer of Aytu BioPharma. Josh, please proceed.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Thank you, Robert, and welcome, everyone. I'm extremely pleased with the operating and financial performance achieved during the twenty twenty five third fiscal quarter. A quick run of our numbers here to get us started. Total revenue grew 32%, led by growth in both our ADHD portfolio, which was up 25%, and pediatric portfolio, which was up 77. The strong revenue growth, coupled with the implementation of our cost reduction initiatives, which helped to decrease operating expenses by $1,600,000 led to income from operations of $2,400,000 It's important to note that this is our second quarter with positive income from operations in the company's history, another huge milestone for everyone here at Aytu.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

I'll note also that this is our third quarter of positive net income from continuing operations and third quarter of positive net income as well. Significant accomplishments across the board. Down the income statement, net income was $4,000,000 which compared to a $2,900,000 loss in Q3 of a year ago, and translates into basic earnings per share of $0.65 this quarter compared to a $0.52 loss in the year ago third quarter. And finally, adjusted EBITDA came in at $3,900,000 compared to $900,000 in the year ago third quarter. By nearly every financial metric there is, we had a phenomenal third quarter.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

While it has taken a bit of time to fully get to this point, the pieces we've been putting in place for the past number of quarters, have focused our efforts on our prescription pharmaceutical business, are beginning to fully manifest themselves in our financial performance. Remember, over the past two years, we have halted our clinical development efforts, wound down and sold our consumer health business, outsourced our manufacturing to a U. S.-based CMO, and refinanced our long term note on more favorable terms. These have been heavy lifts, but the results announced today highlight what is possible as we move this business forward. The beauty of where we sit today is that these positive financial results are being accomplished on a focused portfolio of products.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

I believe our commercial platform has the ability to be further leveraged in the future through additional in licensed or acquired products that can utilize the capabilities of our CNS focused sales team and the broader A2 RxConnect patient access platform. This is something we are keenly focused on now and in the future. But first, back to our two current product focuses, starting with ADHD. As I mentioned, ADHD net revenue was up 25%, coming in at $15,400,000 during the quarter compared to the year ago quarter. Sequentially, ADHD net revenue also increased, up 11%.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Certainly strong performance from the entire commercial organization that we're very pleased with. Overall, ADHD prescriptions were approximately 94,000 during the third quarter. Looking more broadly at the ADHD stimulant market, we continue to see conditions returning to a more normalized state following a series of significant market wide stimulant shortages commencing in early twenty twenty three that impacted the supply of Adderall XR and amphetamine based products as well as methylphenidate based stimulant medications. As I've discussed, fortunately, A2 supply was never impacted, and we therefore realized short term and long term tailwinds from the shortages others we're facing. With the market stabilization in effect, the ADHD net revenue growth was largely driven by organic growth and improvements in gross to nets through assertive management of our brand's economics.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

This, of course, is enabled through our A2 RxConnect platform. Gaining strong channel and dispensing insights, and therefore the ability to manage our per script economics, is a calling card of A2 RxConnect, so it was encouraging this quarter to see these GTN improvements. We saw a benefit from savings offers, government rebates, commercial rebates, and distributor fee improvements, and also took a slight price increase in January of this year. It was a favorable quarter across multiple GTN parameters to be sure. But back to what I believe is a key driver in all of this, HQ RxConnect, our flagship best in class patient access platform.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

RxConnect continues to be a significant differentiator for the company and one that enables us to stand apart from the competition and truly benefit patients. As a reminder, RxConnect is among other things, a network of about 1,000 pharmacies with which we work around the country. Many of these are independent pharmacies in local geographies that do an excellent job servicing patients and prescribers. They're small businesses that work very hard to serve patients well and to go above and beyond to deliver best in class patient experiences. The other part of our network is made up of regional grocery chains that are very customer centric, that provide excellent customer service and work directly with us to ensure patient access to our products and the optimal use of our savings offers.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

I dove into this during our last quarter a bit, but as a reminder, the biggest differentiators of A2RX Connect is our ability to cut through the opaqueness of the pharmacy model to offer prescribers and patients affordability, predictability, and access, irrespective of a patient's insurance or their plan design, and even during the high deductible season when many patients experience higher out of pocket costs. Ultimately, with RxConnect, we are putting the power back into the hands of physicians and patients, something both stakeholders so desperately need today. Today, more than 85% of the company's scripts are driven through the A2RS Connect network. Again, this is something we think can be leveraged in the future as we look to bring in other products to the portfolio. Transitioning now to the pediatric side of the business.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

As I mentioned at the beginning, pediatric portfolio net revenue increased 77% to $3,100,000 compared to the prior year period. Sequentially, the pediatric portfolio net revenue increased 27%. Growth in peds reflects the positive effects from a recently implemented return to growth plan, as well as improvements in product gross to nets. As a reminder, looking back a few quarters ago, we were impacted by a variety of payer and channel challenges. Initially, we saw the impact when a large payer stopped covering a big portion of pediatric fluoride based multivitamins that affected the entire multivitamin plus fluoride class.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

This was exacerbated further as we had some fairly concentrated dispensing pharmacies where this payer has a large market share. Our antihistamine was affected similarly by a payer change in an area where we had a pretty significant concentration of prescribers with that product largely covered by Medicaid. We have put in place a series of initiatives focused on diversifying the prescriber base and improving payer coverage for both franchises, multivitamins, as well as with our antihistamine franchise. In particular, we have focused on expanding areas of promotion, diversifying our base of dispensing pharmacies, and bringing on several payers that we hadn't had covering our products before. We've also deployed sales representatives and shifted some promotional resources to our pediatric products.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Previously, pediatric sales were conducted with a much smaller group of sales specialists that focused on promoting those products. For the last couple of quarters, we shifted our sales forces product mix, providing for a better balanced and more impactful product penetration, and specifically with increased short term emphasis on those pediatric products. We'll prudently allocate resources and evaluate the most appropriate product promotional mix to leverage our sales force most effectively. We'll also of course monitor all macro and political factors that could have the potential to impact our brands, whether that be our ADHD brands, our fluoride supplements, or our antihistamine franchise. And of course, we'll then shift accordingly in terms of our priorities.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Being nimble and responsive to what we believe are our best growth drivers is a critical success factor here for Aytu, so we'll always focus resources on the products we believe can drive the most growth, depending upon all commercial and macro factors we track. Clearly, the work we have done in the last six to twelve months is starting to be highlighted more fully in our financial results. As we have stated for some time now, we first and foremost are focused on the continued organic growth of our ADHD and pediatric portfolios. Today's results highlight our execution on that initiative. Second, we have focused on driving efficiencies across the organization.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Again, that started with our decision to stop our development work, continued with our shutdown and sale of our consumer health business, expanded with the outsourcing of our manufacturing, and concluded in some ways with the optimization initiatives we announced recently to cut out an additional $2,000,000 annually from our operating expenses. All of these moves are nearly fully recognized in the results you see today. With our infrastructure near full optimization, we remain focused on leveraging our platform through the pursuit of additional in licensed or acquired products that can utilize the capabilities of our CNS focused sales team and the broader A2 RxConnect patient access platform. We are adept at identifying valuable assets and aligning with partners to seek a commercial partner with unique capabilities. So we see a tremendous advantage and a tremendous opportunity, rather, to leverage our infrastructure, our capabilities, and our expertise and to diversify our portfolio by in licensing and or acquiring assets.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Of course, we'll be smart about it and look to pick these assets up as attractively as possible in win win transactions for us and our prospective partners. As you can hear, I'm extremely pleased with the progress made and the results being more fully manifested in our financial results. In some ways, this was the type of breakout quarter that we always knew we were capable of when we implemented the series of strategic initiatives over the past couple of years. It's great to see it come to fruition. Let me now turn the call over to Ryan to review the financials in more detail, after which I'll provide a few closing comments, and we'll be happy to take your questions. Ryan?

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

Thank you, Josh. As you mentioned, the twenty twenty five fiscal third quarter's results underscore the hard work, dedication, and perseverance of the entire AQ team. Our financial progress highlights the huge number of operational and financial changes that we've worked on over the past few years. Please note that our March 2025 financial results are detailed in both our press release and Q3 fiscal twenty twenty five Form 10 Q that we filed today with the SEC. Let's dive into the numbers in more detail.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

The third quarter net revenue was 18,500,000.0, up 32% from 14,000,000 in the year ago third fiscal quarter. The ADHD portfolio net revenue rose 25% to $15,400,000 versus $12,300,000 in Q3 fiscal twenty twenty four, primarily reflecting improvements in our gross to net that we spent a lot of time optimizing and constantly refining. On the pediatric side, net revenue was $3,100,000 versus $1,700,000 in Q3 of last year. As Josh noted, we continue to see the progress in the execution of our pediatric Return to Growth program and are pleased with our results, which again showed a rebound both year over year and sequentially. Gross margin for the third quarter was 69% compared to 74 in the Q3 of last year.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

Last quarter, had mentioned the noise in our numbers, especially in our cost of sales. We are and expect to continue to work through the higher cost inventory through the end of this fiscal year, which ends on June 30. As a reminder, from a GAAP accounting standpoint, earlier this year, we loaded factory overhead costs into the ADHD inventory manufactured at our now shuttered Grand Prairie facility. We did this as we ramped down our own manufacturing and ramped up production at our contract manufacturer, which ensured a balanced manufacturing handoff. As our self manufactured production output fell, the in house produced goods absorbed to the same amount of overhead from our facility and personnel.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

Thus, the numerator or the overhead expense stayed constant while our denominator or manufactured units fell, and as a result, resulted in higher unit cost of goods. As we continue to sell through this inventory, we expect to see our ADHD gross margins expand. Breaking down our cost of goods slowed slightly during the third quarter, of the overall $5,600,000 3 hundred and 50 2 thousand dollars represent the current year depreciation and amortization, 1,500,000.0 represents overhead and indirect costs, with direct costs consisting of the remaining 3,800,000.0 With continued revenue growth, we expect to see gross profit margins improve toward the low to mid 70% range and see operating margins reflect our reduced headcount, leaner management structure, and, of course, outsourced manufacturing. Operating expenses in Q3, excluding amortization of intangible assets and restructuring costs, were down $1,300,000 to $9,500,000 from $10,800,000 last year. The decreased OpEx is a result of our focus on continued cost reduction and our improved operational efficiencies.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

One note about our last year's numbers. The consumer health care business is now accounted for as discontinued operations. Thus, last year's expense excludes that division's revenues and expenses. If you were to look at the actual OpEx from the year ago quarter, the savings are significantly greater. Net income from operations during this quarter was $2,400,000 versus last year's loss from operations of $1,600,000 or a $4,000,000 swing in earnings.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

Bottom line net income during the third quarter of fiscal twenty twenty five was $4,000,000 or $0.65 net income per share basic and $0.21 net income per share diluted compared to a net loss of $2,900,000 or $0.52 net loss per share basic and diluted in the prior year period. The fiscal twenty twenty five third quarter results were impacted by $2,300,000 of derivative warrant liability gain due primarily to the decrease in the company's stock price compared to a derivative warrant liability gain of $1,000,000 in the third quarter of fiscal twenty twenty four. To reiterate from earlier, the positive operating income of $2,400,000 is our second quarter with positive income from operations in the company's history. And again, this is our third quarter of positive net income from continuing operations and positive net income overall. For the quarter, adjusted EBITDA was $3,900,000 in the third quarter fiscal twenty twenty five compared to $900,000 in the prior year period.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

A full reconciliation of adjusted EBITDA is included in the press release. This puts our trailing twelve month EBITDA at $9,200,000 Turning now to the balance sheet. The cash and cash equivalents were 18,200,000.0 at 03/31/2025 compared to 20,400,000.0 at 12/31/2024. I do wanna note that the biggest change in the balance sheet was from the growth of our accounts receivable, which show at 35,800,000.0, up from last June's '20 '3 point '5 million. While our sales can be somewhat lumpy, our collections are very predictable.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

We collected about 19,000,000 of those receivables in April and expect that the remainder will come in during May per our normal trade terms. On the liability side of the ledger, we're in full compliance with all our debt covenants. We u we did use some of our cash holdings to pay down a combined 2,500,000 in long term debt and other fixed payment arrangements during the third quarter of fiscal twenty twenty five. While we don't provide forward guidance, I will say that overall, we are very pleased with the progress that Aytu has made in getting to this point in time. Our hope is that as we approach the end of our fiscal twenty twenty five year, we are well positioned to take advantage of the growth in our underlying business.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

With that, let me turn it back over to Josh.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Thank you, Ryan. Let me just say that it's very gratifying when a plan comes together the way our multi year strategic realignment to focus the plan has come together. Let's not forget that in fiscal 'twenty one, we had a net loss of $58,300,000 and an adjusted EBITDA loss of $34,800,000 We were burning cash and taking significant impairments on our assets. Today, we have recorded three consecutive quarters of positive net income and eight straight quarters of positive adjusted EBITDA. We've utilized the opportunity to improve the balance sheet through the continued pay down of our long term loan with Eclipse, our senior lending partner, and other fixed payment arrangements.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

As Ryan mentioned, we paid down $2,500,000 this quarter alone. The sales team and our A2 RxConnect platform are operating at high levels of efficiency. And as Ryan just highlighted, we still have upside potential within our gross margins as we fully finalize the outsourced manufacturing transition. All of this would not have been possible without the hard work of the entire A2 team. I look forward to building off this success in the future, and I thank the whole team here for their efforts to get us to this important point.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Thank you to everyone participating on today's call. We'll now be happy to answer any questions. Operator?

Operator

You. And the first question is coming from Nas Raman from Maxim Group. Nas, your line is live.

Naz Rahman
Analyst at Maxim Group

Hi, everyone. Thanks for taking my questions and congrats on the progress made, especially over all these years. For this quarter, did you see any one time effects in the ADHD or pediatric business, whether it's stocking or anything else that impacted the numbers?

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

No, thanks, Nas, for the question. The answer is no on that on both fronts. This was organic growth driven by obviously all the optimization efforts, but there's no one timers in there at all, nothing related to stocking. So very good to see that.

Naz Rahman
Analyst at Maxim Group

Got it. And on that point, it seems like the ADHD franchise is finally back to a level seen at late fiscal twenty three, early fiscal '20 '4. Are these levels you expect to continue growing forward? Or do you expect to see growth here? Guess based on what you've seen thus far in the current quarter, what are you sort of expecting and seeing?

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Yeah, we do certainly expect growth going forward. And yeah, I appreciate you acknowledging that we're sort of back to historically high levels, following just some optimization efforts that have happened along the way. And as we continue to focus obviously on the ADHD products along with the pediatric products, I think we've really developed a good balance and prioritization across the portfolio to enable growth of both portfolios. So yeah, very excited with your trajectory. The sales team's really begun to get optimized and operate with good efficiency.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

And so, yeah, excited to think that we can maintain and even grow these levels. So, yeah, very good momentum.

Naz Rahman
Analyst at Maxim Group

Got it. And on a similar energy on the pediatrics business, you're now returning to growth or like sales level not seen, I guess somewhere between like late fiscal twenty twenty three, early fiscal '20 '20 '4. Where do you sort of see the franchise going or getting back to? Do you think you can still go back to becoming like a $25,000,000 annual business or you think it's less than that? What do think the potential for the pediatric business is now?

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Yeah, probably not quite to that level, Nas. We would realistically expect growth to some degree from these levels, but probably not to that $25 plus million annualized run rate. But I'd always sort of said, we'd be pleased if we could get sort of halfway back to where it was. So something north of where it is today, but perhaps not at, again, that $25,000,000 level. So I don't want to guide specifically, but if you take a look at this quarter and potentially applied some growth to that, I think that's a realistic number.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

We're seeing really good momentum on the antihistamine franchise in particular. There's probably more substantial growth in that particular franchise than perhaps with the multivitamins various reasons and ultimately think we can grow that product. But yeah, I think something approximating and maybe exceeding halfway where they were would be a good number and that would make these a meaningful contributor for the company while we think we can continue to grow the ADHD franchise as well.

Naz Rahman
Analyst at Maxim Group

Got it. Thanks. And I guess on the big business development front, what have been, I guess, the gaining factors in potentially closing a deal? Is it more like you're having some of just finding the correct asset? Is it the asking price? And also what have you seen in terms of valuation? Have valuations like come down in the last several months amidst like market volatility? Have they been relatively stable? Have they increased? Like what have you been seeing and what have been the gating factors to potentially closing some sort of transaction?

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Yeah, I'd say the main gating factor for us is the right fit. We're really looking for the right asset to complement the capabilities, the therapeutic focus, the Salesforce footprint, and of course the RxConnect capability that we're obviously very proud of. And so we would be optimally looking for something aligned to what the Salesforce does on a regular basis, which is largely calling on psychiatrists, and to some degree pediatricians. And so that's been the biggest factor, is finding just that right asset. And I'll remind you that we're open to assets at various stages, most preferably something that's commercial ready, commercial stage, potentially something that's on the market, but the sweet spot would be something that is on the market and or ready to be marketed vis a vis through, it's already been through the FDA approval process.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

So that's been the main thing is just finding the right thing. I'll say, look, we're excited about some of the things that we have, that we're evaluating some of the things we have on our plate at the moment. And I think we can get something done here in the relative near to mid term. We've said it's a high priority for the company to bring in an asset that's complementary, but we don't want to bring in just any asset for the sake of it. We are willing to look at brands that need to be launched.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

We're also willing to look at brands that need to be relaunched in some cases. And of course, we're open to mature assets that we believe can be accretive. The answer on valuation, I would say the valuation is going to have to be right for us. Obviously, we want to use our cash judiciously, particularly in this environment where cash remains very precious to us and we have priorities not just around launching a product, but also around managing the debt and paying that down. Valuations are a bit high, obviously in this environment, companies are holding on to their assets more, and so the valuations are higher.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

But I'm increasingly confident that we're going to be able to bring in an asset that really well aligns with therapeutic focus, our footprint, and with our capabilities. So more to follow, but excited about the things we have kind of circulating at the moment.

Naz Rahman
Analyst at Maxim Group

That was very helpful. Thanks. And one last question, if I may. In context of the broader political environment, what tariffs have any impact on A2? And if so, how?

Naz Rahman
Analyst at Maxim Group

Or is there any other piece of legislation that you think might have any material near or medium term impact on A2?

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Yeah, good question. I'd say in the context of tariffs, as it relates to our products, relatively de minimis impact, understanding that our ADHD meds are all of our products are manufactured in The US. Just to restate that, we've mentioned that I think in the past. The ADHD products by definition are made in The US. The DEA does not allow you to import amphetamine or methylphenidate.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

And so by definition there's minimal impact. We have sort of small componentry that would be sourced outside The US that would have some level, be impacted to some degree from but it's not a material amount. Same applies for our other products, carbinol and the multivitamin franchise. While there are components that we pull in from outside The US, for example, one of the key ingredients in our multivitamins does come from Europe, but it's a relatively small purchase price in the scheme of things. And again, those products are all finished here.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

So would not expect tariffs to have any material impact. As it relates to other potential macro factors out there, there's been talk, particularly recently, around fluoridation. Some states have recently banned putting fluoride in the municipal water supply. Utah is one state that has recently enacted that, and that'll take effect here very, very quickly. Other municipalities are seemingly daily making the move to potentially remove fluoride from the water.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

So we're monitoring that. What impact does that have on the upside remains to be know, equal parts, there's talk of the FDA evaluating fluoride and fluoride supplements as to their benefits and the utility, and there is the potential that they at some point down the road, you know, conduct a study. They've indicated as much that they plan to study fluoride supplements here and come out with at least a recommendation. What impact that has, I mean that has a long ways to go in terms of whether that even becomes close to reality. There's certainly, we've had the thought already, understanding that that's relatively new news.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

It may challenged in court, the American Dental Association continues to be very strong proponents of fluoridation and fluoride supplementation, so it remains to be seen whether any action would be taken, but we'll monitor that, understanding that the pediatric multivitamins are not gigantic pieces of our business today, and if there were any action, we think it would take quite some time if it ever actually comes to fruition. So those are a couple of things as we think about the business, but overall, certainly minimal, if any impact from a materiality standpoint from a tariff perspective. So we feel good about that.

Naz Rahman
Analyst at Maxim Group

Got it. Thanks a lot for taking my questions. And once again, congrats on the quarter.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Thanks, Nas. Appreciate it.

Operator

Thank

Robert Blum
Managing Partner at Lytham Partners

Josh and Ryan, this is Robert here. While we wait to see if there are any additional questions from the teleconference line, we have a couple of questions here. Maybe Josh, the first one for you here. You referred to the return to growth plan for the pediatrics business. But can you revisit the substance of that plan and specifically what entailed related to that?

Robert Blum
Managing Partner at Lytham Partners

To what degree did you pivot the commercial team to get the products back to growth?

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Yeah, thanks Robert. I would say, look, we first and foremost, we did deploy the sales force against more pediatric targets than we had in the past, specifically looking at antihistamine allergy targets. So that was one thing. And so, not to suggest that we took them away from ADHD, but we certainly did add carbon all to their promotional priority, and so that was one thing that we did. We also did expand the footprint significantly more reps in more places than we had been before.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

We had a relatively small team that was active, mostly in the areas where there was quite favorable coverage. So we've deployed more folks in the field around that, again, having dual responsibility for both the ADHD products as well as Carbonyl in particular to create sort of hybrid responsibilities, and so that has certainly served to drive some growth. And then numerous pieces on the payer front to pick up additional coverage, particularly on the public payer side as it relates to the antihistamine franchise. Several states that had previously not been covering the product through some creative contracting and various strategies we've employed across the franchise, we've been able to pick up multiple state Medicaid plans. Previously, Carbonol had been covered in really a very small handful of states and the coverage, I will say, heading into the spring allergy season has picked up materially, multiples more in terms of the number of states that have the product now covered on the formulary, in many cases without any kind of prior authorization or any kind of restrictions.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

As a capstone to all that, I would say just put more emphasis in general on the pediatric franchise, while not letting our foot off the gas on ADHD, and that has certainly served to really help us. So we feel like Carbinal in particular has some really good momentum and good upside from these current levels. That having been said, as I mentioned in my prepared comments, we'll continue to evaluate promotional priorities in the mix in the field. You never stay stagnant and static, definitely want to make sure you're adhering to market trends. Obviously growth drivers are going to be what we put the most emphasis behind, and in the foreseeable future, obviously, we're fully back to promoting the ADHD brands along with Carbonol, and so excited to see that as it unfolds, but good momentum across the portfolio on the basis of some of this return to growth plan that we put in place.

Robert Blum
Managing Partner at Lytham Partners

Okay, great. Next question here, and you touched on this a bit with Nas, maybe if there's anything you can add here as it relates to new product opportunities. How are you thinking about potential product targets? Anything to add there?

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Yeah, all I would say, just to reiterate, again, the sweet spot for us, bull's eye, so to speak, would be something in the CNS space, so something that's in psychiatry, neurology, but with a potential secondary emphasis in the pediatric types of products and some good conversations happening with things that are sort of aligned to that. We clearly are going after brands, we are definitely interested in things that are commercial stage, commercial ready, I. E. Already approved through the FDA and can be launched in relatively short order, or products that are already in the market that we can potentially bring back or reinvent, so to speak. And again, we definitely want things that ideally, if we can get them that fit well within the call point, we've got a sales team that's out there actively engaging with psychiatrists, and to a lesser extent pediatricians, and select family practitioners.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

We're obviously in psychiatry by virtue of the fact that we're in ADHD, and so something that aligns to that. Again, a branded asset on market or ready to be launched would be really in the sweet spot of what we're looking for. We also want things that align well with our payer strategy and fit within the RxConnect platform, things, again, that we understand the nuance around the payer challenges, how to work within the current confines of the PBM ecosystem, and obviously how to work with our pharmacy partners to ensure that there's good value created for everyone in the value chain, the patient, the physician, and obviously the dispensing pharmacist as well. So you mix all those things together and it does create sort of a pretty specific bull's eye, but I think if we can find the right asset, it will be one that we can surely say is a really perfect fit and one that we really can mobilize around. Excited with some of the conversations that we're having.

Robert Blum
Managing Partner at Lytham Partners

All right, great. And then last question maybe for Ryan here with OpEx having come down materially over the last four plus quarters or so. How do you think about the go forward quarterly OpEx line? And what's a good breakeven number based on the current spend there?

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

Yeah. Thanks, Robert, and thanks for the question. And, yes, you're correct. Over the last four years, we've continued to experience reduction in the operating expenses as we've improved kind of the efficiency of the operations to be sold to consumer health division, outsource the manufacturing of ADHD products. Excuse me.

Ryan Selhorn
Ryan Selhorn
CFO at Aytu Biopharma

We finally hit a point this quarter which demonstrates that expenses that we currently expect to continue into the future periods to come. As you'll note in the Q3 results, we do not incur any restructuring expenses and don't anticipate such expenses in the future. Our cash based operating expenses for the quarter, which excludes amortization, depreciation, stock based compensation, totaled $9,300,000 with our overall operating expenses of about $10,400,000 So when analyzing breakeven number from an overall operation standpoint and factoring in a similar gross profit accomplished this quarter of 69.4%, revenue would need to achieve approximately 15,000,000 on a quarterly basis to breakeven. But if we eliminated the noncash expenses and calculating kind of a breakeven from an operating cash perspective, total revenue would would be closer to about 13,100,000.0, to hit that breakeven point.

Robert Blum
Managing Partner at Lytham Partners

All right, fantastic. Josh, Ryan, not showing any additional questions here. So Josh, I guess I'll turn it over to you for closing remarks.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

Great. Thanks, Robert, and thanks to everyone on today's call for your time. We appreciate everyone's interest in Aytu BioPharma. We really are very pleased with the progress that we've made over the last couple of years. It has been a long time coming.

Josh Disbrow
Josh Disbrow
Chief Executive Officer at Aytu Biopharma

We appreciate everyone's patience as we enact many of these significant changes to transform the company to get ourselves into the position that we are today. So with that, I'll say again, thanks for your time, thanks for your interest, thanks for your ongoing support of Aytu, and we look forward to sharing our full fiscal twenty five year end results in the fall in September when we file our 10 ks and subsequently release earnings for the fourth fiscal quarter, which is off to a very, very good start. So with that, I wish you a good afternoon and a good evening. And again, thanks for your time. Have a good evening.

Operator

Thank you. This does conclude today's conference. You may disconnect your lines at this time. Thank you for your participation.

Analysts
    • Robert Blum
      Managing Partner at Lytham Partners
    • Josh Disbrow
      Chief Executive Officer at Aytu Biopharma
    • Ryan Selhorn
      CFO at Aytu Biopharma
    • Naz Rahman
      Analyst at Maxim Group
Powered by Quartr